Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05863416

Dexmedetomidine in Non-intubated VATS

Adjunctive Dexmedetomidine Infusion in Non-intubated Video-assisted Thoracoscopic Surgery

Status
Recruiting
Phase
Phase 4
Study type
Interventional
Enrollment
144 (estimated)
Sponsor
Tri-Service General Hospital · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

This prospective study aims to evaluate the effectiveness of intraoperative DEX for postoperative analgesia and recovery after non-intubated VATS. In addition, the investigators observe the impact of DEX on anesthetic requirements, hemodynamic parameters, and adverse events during non-intubated VATS.

Detailed description

The non-intubated thoracoscopic approach has been adapted for use with major lung resections. The non-intubated VATS tries to minimize the adverse effects of tracheal intubation and general anesthesia, such as intubation-related airway trauma, ventilation-induced lung injury, residual neuromuscular blockade, and postoperative nausea and vomiting. An adequate analgesia allows VATS to be performed in sedated patients and the potential adverse effects related to general anesthesia and selective ventilation can be avoided. Dexmedetomidine (DEX), a highly selective alpha-2 receptor agonist, is increasingly used in anesthesia with sedative, hypnotic, anxiolytic, sympatholytic, and analgesic effects. It can also attenuate perioperative stress and inflammation and preserve the immunity of surgical patients, which may contribute to reduced postoperative complications and improved clinical outcomes. This study aims to evaluate the effectiveness of intraoperative DEX for postoperative analgesia and recovery after non-intubated VATS. In addition, the investigators observe the impact of DEX on anesthetic requirements, hemodynamic parameters, and adverse events during non-intubated VATS.

Conditions

Interventions

TypeNameDescription
DRUGDexmedetomidine infusionIntraoperative dexmedetomidine infusion

Timeline

Start date
2024-04-23
Primary completion
2025-06-01
Completion
2025-12-01
First posted
2023-05-18
Last updated
2025-01-07

Locations

1 site across 1 country: Taiwan

Source: ClinicalTrials.gov record NCT05863416. Inclusion in this directory is not an endorsement.